The high risk human papillomavirus (HPV) type 16 E7 protein aects cell growth control and promotes transformation by interfering with functions of cellular proteins. A key target of E7 is the tumor suppressor protein p105RB. Although this interaction is required for E7-dependent transformation, other cellular molecules must also be involved, because some E7 mutants that have reduced transforming abilities still bind to p105RB. In order to identify additional proteins that interact with E7 and that may be responsible to mediate its transforming function, we have used the C-terminal half of E7 in a yeast two-hybrid screen. We identi®ed the fork head domain transcription factor M phase phosphoprotein 2 (MPP2) as an interaction partner of E7. Speci®c interaction of the two proteins both in vitro and in vivo in mammalian cells was detected. The interaction of MPP2 with E7 is functionally relevant since MPP2 enhances the E7/Ha-Ras co-transformation of rat embryo ®broblasts. In addition HPV16 E7, but neither non-transforming mutants of HPV16 E7 nor low risk HPV6 E7, was able to stimulate MPP2-speci®c transcriptional activity. Thus, MPP2 is a potentially important target for E7-mediated transformation.
Introduction
Infection of various types of squamous epithelial cells with human papillomaviruses (HPV) usually gives rise to benign cell proliferation. Certain types of HPV, however, including HPV 16, 18, 31 and 33, infect the genital mucosa and have been strongly implicated in the etiology of malignant carcinomas, especially those of the cervix (for review see zur Hausen and de Villiers, 1994; zur Hausen, 1996) . Several lines of evidence indicate that the E6 and E7 genes of high risk HPVs are responsible for the initiation of tumor formation (for review see Mansur and Androphy, 1993; MuÈ nger and Phelps, 1993; Tommasino and Crawford, 1995) . First, in cervical tumors, the early region of the viral genome is integrated into the host genome, and the proteins E6 and E7 encoded by this region are expressed in the tumor cells (Schneider-GaÈ dicke and Schwarz, 1986; Smotkin and Wettstein, 1986) . Second, E6 and E7 together are sucient to transform primary human keratinocytes in culture (MuÈ nger et al., 1989; Hudson et al., 1990) . Third, each of the transforming proteins can cooperate with an activated form of the oncoprotein Ras in the transformation of primary rat embryo cells (Chesters and McCance, 1989; Crook et al., 1988 Crook et al., , 1989 DiPaolo et al., 1989; Matlashewski et al., 1987; Phelps et al., 1988) . Finally, transgenic mice expressing E7 in epithelial and thyroid cells develop hyperplasias and carcinomas (Auewarakul et al., 1994; Greenhalgh et al., 1994; Herber et al., 1996; Lambert et al., 1993; Ledent et al., 1995) .
Numerous studies have shown that the E6 and E7 proteins aect cell growth at least in part by targeting dierent tumor suppressor proteins (for review see Vousden, 1993) . The most thoroughly studied function of E6 is its destabilizing eect on the tumor suppresor p53 resulting in the loss of a major mechanism to prevent S phase entry or to promote apoptosis in response to DNA damage (Schener et al., 1990 (Schener et al., , 1993 Ko and Prives, 1996) . Such p53-negative cells tend to accumulate mutations that facilitate tumor progression (for review see zur Hausen and de Villiers, 1994) .
The E7 protein targets another cellular growth control pathway, in that it binds to the pocket regions of the retinoblastoma protein p105RB and the related protein p107 and thereby compromises their functions (for review see MuÈ nger and Phelps, 1993; Tommasino and Crawford, 1995) . Binding of p105RB to E2F transcription factors results in an active repressor complex, which negatively regulates E2F target genes important for S phase progression (for review see Weinberg, 1996; Zwicker and MuÈ ller, 1997; Mulligan and Jacks, 1998) . This repression is relieved by cell cycle-regulated cyclin-dependent kinase (CDK) phosphorylation of p105RB. Binding of E7 to p105RB is functionally similar to the CDK-dependent hyperphosphorylation of p105RB in that it leads to the activation or derepression of E2F-regulated transcription and thus promotes S phase progression (Phelps et al., 1991; Lam et al., 1994) .
Much of the available evidence suggests that interference with the activity of the tumor suppressor protein p105RB is the predominant pathway by which E7 enhances cell proliferation (Edmonds and Vousden, 1989; Phelps et al., 1992) . Nevertheless, other factors clearly contribute to E7-induced transformation. For instance, mutations of the N-terminal region and the protein kinase CK2 (formerly casein kinase II) phosphorylation sites in¯uence transformation (Banks et al., 1990; Brokaw et al., 1994; Firzla et al., 1991) . In fact, the replacement of the two Ser-residues of the CK2 site with Ala inhibits the transforming potential of E7 without altering binding to p105RB. Furthermore, some mutations within the C-terminal Zn-®nger domain inhibit E7 transforming activity (Phelps et al., 1992; McIntyre et al., 1993) and impair the ability of E7 to immortalize human keratinocytes (Jewers et al., 1992) . These ®ndings suggest that E7 contacts cellular proteins other than p105RB in exercising its complete spectrum of biological activities.
Some of the properties of E7 beyond those explained by association with p105RB may be due to interaction with cyclin-dependent kinase inhibitors (CKI). Recent ®ndings indicate that E7 can interact with p27 KIP1 and abrogate p27-dependent inhibition of cyclin E/CDK2 kinase and of cyclin A promoter activity (ZerfassThome et al., 1996) . In addition E7 binds to p21
Cip1 and interferes with its ability to inhibit cyclin E/CDK2 and cyclin A/CDK2 kinase activities and proliferating cell nuclear antigen-dependent DNA replication (Funk et al., 1997; Jones et al., 1997) . Also E7 interacts directly with proteins involved in regulating gene transcription, including the TATA-box binding protein (TBP) (Massimi et al., 1996) , TBP-associated factor 110 of Drosophila melanogaster (TAF II 110) (Mazzarelli et al., 1995) , and c-Jun (Antinore et al., 1996) . Although TBP and TAF II 110 bind E7 and may be important for the regulation of gene transcription by E7, it is as yet unclear whether they are important for E7-induced transformation. However a DNA-binding de®cient mutant of c-Jun inhibits E7-mediated transformation (Antinore et al., 1996) . In summary, binding and inactivation of p21 and p27 as well as binding to c-Jun, together with interfering with the function of pocket proteins, are likely to contribute to E7's ability to overcome negative growth regulatory signals.
In order to identify additional proteins that are targeted by HPV16, we have performed a two-hybrid screen in yeast. By this method, we have identi®ed several novel potential interaction partners that bind to the C-terminal half of E7. One of these partners was represented by four overlapping clones whose sequences were homologous to a previously identi®ed partial cDNA encoding M phase phosphoprotein 2 (MPP2) (Westendorf et al., 1994; Matsumoto-Taniura et al., 1996) . We have cloned cDNAs encoding fulllength MPP2, which has recently been identi®ed as a transcription factor of the fork head (fkh)/winged-helix family of proteins [HFH-11 (Ye et al., 1997) , WIN (Yao et al., 1997) , Trident (Korver et al., 1997a) ]. We demonstrate that MPP2 binds to E7 and aects E7-induced transformation, and that E7 of HPV16, but not of HPV6, can stimulate transcription of MPP2. Our data suggest that MPP2 represents a novel target protein of E7 that might be important for transformation.
Results

Identi®cation of MPP2 as a potential HPV16 E7 interaction partner
The ability of HPV16 E7 to bind to the retinoblastoma protein p105Rb is necessary but not sucient for transformation. That is, some mutations of E7 that do not prevent binding to p105Rb aect the transforming potential of E7. These phenotypes suggest that E7 contacts proteins other than p105Rb in the process of bringing about cellular transformation. In order to identify such proteins, we employed the yeast twohybrid system. To ®nd an E7 fragment suitable for use as a bait protein, we prepared plasmids encoding the DNA-binding domain (aa 1 ± 102) of the bacterial LexA protein fused to various E7 fragments ( Figure  1a) . The introduction of all but one of the plasmids led to activation of LexA-dependent transcription as demonstrated by growth of the transformed L40 yeast cells on His 7 plates (Figure 1b) . Any LexA DNAbinding domain-E7 fusion protein containing the amino terminus (up to aa 40) of E7, even those with mutations in the p105Rb binding or the CK2 phosphorylation site, activated LexA-dependent transcription of the (lexA) 4 -HIS3 reporter gene. These ®ndings are consistent with previously published observations (Clemens et al., 1995; Zwerschke et al., 1996) . By contrast, cells expressing LexA-E7(42 ± 98), like those expressing LexA alone, were not able to grow on His 7 medium and, therefore, were suitable for isolation of E7 interaction partners in the two-hybrid screen.
L40 yeast cells expressing the LexA-E7(42 ± 98) fusion protein were transformed with a library of cDNA fragments derived from mouse embryo RNA fused to the Herpes simplex virus VP16 transactivation domain. Colonies of transformed cells that grew rapidly on plates lacking histidine were restreaked on agar plates containing X-gal to test for activation of LexA-dependent transcription of b-galactosidase. cDNA library plasmids were isolated from the 30 colonies that developed the most intense blue color, and these plasmids were rescreened for their ability to induce LacZ expression in the presence of LexA-E7(42 ± 98) in L40 cells. Of these 30 plasmids, 28 scored positive.
To determine whether these interactions were speci®c to E7(42 ± 98), other target proteins were tested: LexA-Myc(49 ± 101), and LexA alone. Five of the 28 library plasmids showed activation of LexA-dependent transcription with LexA-Myc and/or LexA-lamin C as well as LexA-E7(42 ± 98) and were not analysed further. None induced the test promoter in cells containing the LexA DNA-binding domain alone (data not shown). Because the remaining 23 plasmids activated only LexA-E7(42 ± 98), they were considered to code for potential E7-interacting proteins. Sequencing of the inserts of these 23 plasmids indicated that four of them contained cDNA sequences derived from the same mRNA. In three of these, clones 5, 1/5 and 3/5, the insert was identical. The insert of clone 21 contained a smaller cDNA fragment, truncated on both ends relative to the other three clones (Figure 2) . The 3' 171 nucleotides of clone 1/5 were highly homologous (78% identity) to our previously described, partial human cDNA (clone 5-3) encoding a portion of M-phase phosphoprotein 2 (MPP2; Westendorf et al., 1994) . The other plasmids will be described in detail elsewhere.
Using clone 5-3 of hMPP2 and clone 1/5 of mMPP2, we isolated several clones from a HeLa cDNA library and from a murine embryonic (d 11.5) cDNA library, respectively. Clone 2C1 contained the complete ORF of hMPP2 and was used for the subsequent experiments. The human and mouse sequences obtained by us are apparent splice variants of the recently published sequences for HFH-11, WIN and Trident (for details see Figure 2 ).
hMPP2 binds to GST-E7 in vitro
To substantiate the interaction of E7 with hMPP2, we performed in vitro binding assays. E7 was translated in vitro in the presence of (Korver et al., 1997a; Yao et al., 1997) . In addition a splice variant of hWIN encoding a protein with a 15 aa deletion spanning the C-terminal end of the fkh domain was identi®ed. This form of MPP2 was also identi®ed as hHFH-11B (Ye et al., 1997) . A third splice variant (hHFH-11A) contains an additional 38 aa in the region between the fkh domain and the E7 interaction domain (as indicated). While no splice variants were found for either mMPP2 (our unpublished data) or mTrident (Korver et al., 1997a) , rWIN represents most likely a forth splice variant of the same gene with an insertion coding for 12 aa in the fkh domain. The human, rat, and murine MPP2 sequences are highly homologous and the identities of any two of the three sequences are in the range of 80% if the dierentially spliced exons are not taken into account. The mMPP2 fragments 1/5, 5, 3/5, and 21 that were identi®ed in the yeast two-hybrid screen are indicated (clones 1/5, 5, and 3/5 were identical)
Only background binding was observed to GST and GST-Max. In contrast a substantial amount of binding was seen with which contains the E7 interaction domain (aa 488 ± 584 of MPP2, see Figure 2 ) as identi®ed in the two-hybrid screen but not with GST-MPP2(235 ± 335) or GST-MPP2(1 ± 477) lacking this domain ( Figure 3a ). In addition hMPP2 was translated in vitro and incubated with dierent GST fusion proteins or with GST alone (Figure 3b ). While hMPP2 was found in complexes with GST-E7, little or no binding to GST-E7(2 ± 41), a fusion protein lacking the C-terminal 57 aa, GST-Max, or GST was observed. Together these ®ndings demonstrate speci®c in vitro interaction between hMPP2 and HPV16 E7.
In vivo interaction between MPP2 and E7
The ®ndings described thus far indicate that MPP2 and E7 form a complex in vivo in yeast and in vitro. To test whether an MPP2-E7 complex could also be detected in mammalian cells, we co-expressed hMPP2 and E7 in COS-7 cells. After metabolic labeling, immunoprecipitations using MPP2-speci®c or control (rabbit antimouse) antibodies were performed from cell lysates prepared under mild detergent conditions ( Figure 4 ). The immunoprecipitated proteins were then released from the beads in AB buer and reprecipitated using control antibodies (Figure 4, 2nd IP) . No E7 was detected in these samples but MPP2 was re-immunoprecipitated due to the release of some MPP2-speci®c antibodies from the ®rst immunoprecipitate ( Figure 4 , lanes 1 and 3). The unbound proteins were then analysed for the presence of E7 using speci®c antibodies ( Figure 4 , 3rd IP). E7 was speci®cally detected in the sample obtained from the anti-MPP2 immunoprecipitation but not from control samples ( Figure 4 , lanes 2 and 4). Immunoprecipitations using either rabbit anti-mouse, MPP2-speci®c, or E7-speci®c antisera without further treatment were used as molecular size controls (Figure 4 , lanes 5 ± 7). Similarly, co-immunoprecipitation of E7 and MPP2 was observed in lysates of primary rat embryo ®broblasts stably transfected with plasmids expressing Ha-Ras, E7, and MPP2 (data not shown). Thus these ®ndings document a detectable, albeit weak, interaction of MPP2 and HPV16 E7 in mammalian cells.
To further substantiate the observed in vivo interaction between E7 and MPP2, we asked whether hMPP2 could aect the transcriptional properties of a Gal4 DNA-binding domain-E7 fusion protein (Gal4- In vivo interaction of E7 with MPP2. COS-7 cells were transiently transfected with plasmids expressing hMPP2 and E7, labeled with 35 S-methionine/cysteine, and lysed in F buer. For the ®rst immunoprecipitation (1st IP) portions of the lysate were incubated with rabbit anti-mouse serum (control, lanes 1 and 2) or with hMPP2-speci®c peptide antibodies (SC-502, lanes 3 and 4). Co-immunoprecipitated proteins were released in AB-buer and incubated with control serum (2nd IP, lanes 1 and 3). The unbound proteins were then incubated with E7-speci®c serum (3rd IP, lanes 2 and 4). A portion of the F-buer lysate was diluted into RIPA buer and incubated with control serum (lane 5), hMPP2-speci®c antibodies (lane 6), and E7-speci®c serum (lane 7). The proteins were analysed on a 15% SDS ± PAGE and visualized by¯uorography. Prestained molecular weight markers are indicated on the left E7). Since MPP2 has been shown to possess transactivating activity (Ye et al., 1997) we hypothesized that MPP2 would stimulate Gal4-E7-dependent transactivation. Gal4-E7 alone had little or no eect on the p(Gal) 4 -tk-luc reporter gene construct. However coexpression with MPP2 resulted in a signi®cant increase in Gal 4 -E7-dependent transactivation ( Figure 5 ). This was speci®c for Gal4-E7 since no stimulation of the basal reporter activity or of Gal4, Gal4 ± Myc(1-262), or Gal4-Fos by MPP2 was detectable (Figure 5a ). If this transcriptional activation observed with Gal4-E7 and hMPP2 requires an interaction between E7 and MPP2, it should be possible to block this eect by over-expressing an E7 protein that is not fused to Gal4. This was indeed the case; the hMPP2-speci®c activation of Gal4-E7-driven transcription was inhibited by E7 in a dose dependent manner whereas the activity of Gal4-E7 alone was not aected by E7 (Figure 5b and data not shown). The simplest explanation for this interference is that E7 competes with Gal4 ± E7 for binding to hMPP2 thereby preventing the formation of an activation complex on the reporter. This was further substantiated by measuring the activity of MPP2 and E7 mutants. MPP2D426 ± 567, which contains a deletion of the E7 interaction domain, showed little activity together with Gal4-E7 (Figure 5c ). In addition MPP2D588 ± 743 which has a portion of the transactivation domain (TAD) deleted (JM LuÈ scher-Firzla, I Wierstra, H Burkhardt and B LuÈ scher, manuscript in preparation), did not stimulate Gal4-E7-dependent gene expression (Figure 5c ). Since MPP2D426 ± 567 and MPP2D588 ± 743 were expressed equally to MPP2 (data not shown) these data argue that MPP2 can stimulate Gal4-E7-speci®c transcription only when the E7 interaction domain and a functional TAD are present. Furthermore this stimulation required the Cterminal half of E7 while no activation was seen with E7(2-41) (Figure 5c ). This is consistent with the ability The experiments was performed as described in (a). The expression of E7 was titrated by increasing the amount of co-transfected pP2E7 expression vector (1, 2, 3, and 5 mg). MPP2* designates full-length hMPP2 expressed from a plasmid that retains a small open reading frame (sORF) found in the 5' untranslated region of the MPP2 cDNA. This reduces MPP2 expression compared to plasmids with deletions of this sORF and explains the lower induction detected of Gal4-E7-speci®c transactivation in the experiments summarized here as compared to (a) and (c). Mean values and standard deviations of three experiments are shown. (c) The transfections were performed as described in (a). The activation for the dierent Gal4 proteins was set to 1. Gal4-E7 slightly activated transcription (1.3-fold), Gal4 ± E7(2 ± 41) transactivated about twofold compared to Gal4, while Gal4 ± E7(42 ± 98) did not stimulate transactivation. The expression of MPP2, MPP2D426 ± 567, and MPP2D588 ± 743 was equal as measured by Western blot analysis (data not shown). A representative experiment performed in triplicate is shown Figure 6 MPP2 stimulates the transformation of primary rat embryo ®broblasts by E7 and Ha-Ras. REFs were transfected with pras encoding Ha-Ras (Ras), pP2E7 (E7), pSPhMPP2 (MPP2) or the respective empty vectors (7) together with pRSVneo and grown as described in Materials and methods. After 14 days the cells were ®xed and stained with Giemsa and the colonies counted. Three experiments are summarized with six plates/experiment analysed for each individual plasmid combination (with standard deviations indicated) of MPP2 to interact with the C-terminal half of E7. Together these ®ndings support a speci®c in vivo interaction of E7 with MPP2.
MPP2 enhances E7/Ha-Ras co-transformation of primary rat embryo ®broblasts Next, we tested for an eect of MPP2 on E7/activated Ha-Ras-dependent co-transformation. Plasmids expressing hMPP2, E7, and Ha-Ras were transfected into rat embryo ®broblasts together with a plasmid encoding the neomycin resistance gene (Figure 6 ). After 13 ± 14 days, colonies resistant to the neomycin analog G418 were counted. The three proteins Ha-Ras, MPP2, and E7 alone were unable to induce growth of a signi®cant number of G418-resistant colonies. Similarly the combination of E7 and MPP2 did not stimulate the number of colonies. However the co-expression of HaRas with MPP2 resulted in a slight but reproducible increase in the number of G418-resistant colonies compared to Ha-Ras or MPP2 alone. This hints at a potential transforming ability of MPP2 that requires further analysis. On average 23 colonies were obtained with E7 and Ha-Ras which was further stimulated 1.5 ± 2-fold by co-expression of MPP2. This was observd in the three experiments summarized in Figure 6 as well as in several additional transformation experiments (data not shown). Thus cellular MPP2 seems rate-limiting for transformation of ®broblasts with Ha-Ras and E7.
E7 stimulates MPP2-dependent transactivation
To further probe the interaction of E7 with MPP2 we analysed whether E7 could aect the function of hMPP2 as transcription factor. Three binding sites for HFH-11 (Ye et al., 1997) were cloned in front of a Figure 9 HPV6b E7 cannot stimulate MPP2 transcriptional activity. The experiments were performed as described in the legend to Figure 7 with the exception that epitope-tagged versions of HPV16 E7 and HPV6 E7 were used. Eector refers to the constructs expressing either HPV16 E7 or HPV6 E7. Mean values and standard deviations of three experiments are shown minimal tk-promoter/luciferase reporter gene construct ( Figure 7) . Bacterially expressed GST-MPP2(235 ± 335), containing the fkh domain, bound speci®cally to this site (data not shown). Whereas the tk-luc reporter was activated minimally by hMPP2, the reporter with the three MPP2 binding sites was activated on average 2.5-fold (Figure 7 ). An additional 2 ± 3-fold activation was measured when E7 was coexpressed. Small deletions in the C-terminal half of E7, which have been shown previously to inhibit transformation (Phelps et al., 1992) , were unable to stimulate MPP2-activated transcription (Figure 8a ). Because the three E7 mutants used were expressed slightly less eciently than wild type E7 (Figure 8b ), we transfected up to 5 mg of the mutant plasmids without any stimulation of MPP2 activity (data not shown). Thus E7 positively regulates MPP2 transcriptional activity through its Cterminal domain. In addition to the E7 protein of the transforming HPV16 we tested whether E7 of the nontransforming HPV6 could stimulate MPP2 activity. To compare expression levels of HPV16 E7 and HPV6 E7 we used epitope tagged versions of the two proteins. Even so HPV6 E7 was expressed to higher levels than HPV16 E7 (data not shown), it was unable to stimulate MPP2-dependent transcriptions (Figure 9 ). Together the analysis of the dierent E7 proteins revealed a direct correlation between their ability to stimulate MPP2-speci®c transactivation and to cooperate with Ha-Ras in transformation.
Discussion
High risk human papillomaviruses cause human malignancies mainly through the E6 and E7 transforming proteins. While E6 acts primarily through an interaction with the tumor suppressor p53, E7 targets the retinoblastoma tumor suppressor p105RB and other similar proteins (p107), which have key roles in regulation of entry into S phase. Nevertheless, mutational analysis of E7 indicates that all its transforming activity is not based on interactions with retinoblastoma-like proteins. In this study, we searched for other proteins that may play a part in E7-mediated transformation. Using the yeast two-hybrid system, we identi®ed MPP2 as a novel E7-interacting protein and demonstrate that MPP2 can interact with E7 both in vitro and in vivo (Figures 2 ± 5) . Furthermore, the interaction of E7 and MPP2 has functional consequences since MPP2 stimulates E7-dependent transformation ( Figure 6 ) and E7 stimulates MPP2-speci®c transactivation (Figures 7 ± 9 ). Taken together, our results suggest that MPP2 is a novel E7-binding protein that is potentially involved in the generation of human cancer.
While our work was in progress, three publications described the cloning of MPP2-related or homologous sequences. In all three cases degenerate PCR approaches were used to identify novel members of the fkh domain family. HFH-11 was identi®ed in a colon carcinoma cell line (Ye et al., 1997) , WIN in an insulinoma cell line (Yao et al., 1997) , and Trident in thymus tissue (Korver et al., 1997a) . The respective protein sequences are summarized and compared to MPP2 in Figure 2 . Interestingly for the human gene several dierent splice variants that appear to aect function have been found (see below). As yet no evidence for alternative splicing has been obtained for the mouse homolog. The rat gene contains a 36 bp insertion that aects the fkh domain. The identi®cation of MPP2 sequences in various dierent cell types implies that it is expressed nearly ubiquitously. Nevertheless in adult humans and mice the expression of MPP2 seems to be con®ned to a restricted number of tissues, including thymus and testis and to lower levels in small intestine and colon (Ye et al., 1997; Korver et al., 1997a; S Andrecht and JM LuÈ scherFirzla, unpublished) . A more detailed analysis of MPP2 expression revealed that it is associated with proliferating cells such as actively dividing T cells or tissues such as embryonic pancreas, lung, liver, and intestine that contains cycling cells (Yao et al., 1997; Ye et al., 1997; Korver et al., 1997c) . Furthermore, MPP2 expression is induced in regenerating liver upon partial hepatectomy and in serum-stimulated fibroblasts (Ye et al., 1997; Korver et al., 1997a) . Together the data summarized above suggests that MPP2 is found predominantly, if not solely, in proliferating cells, whereas dierentiated or resting cells show little or no expression.
More recently the MPP2 gene was disrupted in mice and the analysis of MPP2 7/7 animals revealed a defect in the developing myocardium (Korver et al., 1998) . This alteration is the likely reason for the observed neonatal lethality. Cardiomyocytes showed polyploidy which the authors interpreted to show that MPP2 is involved in the regulation of the correct succession of S and M phases during the cell-cycle. The ®ndings also suggest that MPP2 is not required for embryonic development of mice. Since MPP2 is expressed during embryogenesis, it will be important to determine whether the full function of MPP2 is non-essential or whether MPP2 is a member of a family of fkh domain proteins that can compensate, at least in part, for each others' function. In this respect it is interesting to note that several fkh domain proteins have been identi®ed as factors involved in dierent aspects of embryonic development (for review see Kaufmann and KnoÈ chel, 1996) .
The ®ndings regarding MPP2 discussed above, i.e. its cell cycle-dependent expression in serum-stimulated cells, the correlation of its expression with proliferating cells, and its role in checkpoint control regulating the interconnection of S and M phase, support a role of MPP2 in cell growth control. Even though the precise function of MPP2 is unclear, the potential role of MPP2 in S and M phase transitions may indicate why this protein is targeted by HPV16 E7. By stimulating the activity of MPP2 as transcriptional activator (Figure 7 ) HPV16 E7 might acquire the ability to modulate a set of cellular genes distinct from those regulated downstream of p105Rb and p21 (MuÈ nger and Phelps, 1993; Funk et al., 1997; Jones et al., 1997) . The ability of HPV16 to enhance MPP2 function might be used to drive host cells into S phase and allow viral replication. In addition our ®ndings suggest that this might be relevant for the ability of HPV16 E7 to transform cells. This is supported by our ®ndings that MPP2 can stimulate E7/Ha-Ras-induced colonies in REFs and that neither HPV6 E7 nor HPV16 E7 mutants impaired in transformation (Phelps et al., 1992; McIntyre et al., 1996) were able to stimulate MPP2-speci®c transactivation (Figures 6, 8 and 9 ). Importantly the chromosomal localization of MPP2 was recently mapped to 12p13 (Korver et al., 1997b) . This site is altered in a number of tumors (for review see Mitelman, 1994 ) but we do not know whether this leads to any alteration in MPP2. Nevertheless high copy number increases of band 12p13 have been found in advanced-stage cervical squamous cell carcinomas that were positive for high risk HPV (Heselmeyer et al., 1997) . This suggests a role for MPP2 in HPVassociated carcinogenesis and the importance of analysing MPP2 in tumors with 12p13 alterations.
For the MPP2 homolog HFH-11 two dierent splice variants were found (see Figure 2) . HFH-11B functions as a transcriptional activator while hHFH-11A is unable to transactivate (Ye et al., 1997) . This is not due to dierences of fkh domain sequences (see Figure  2 ) but due to a 38 aa insertion C-terminal of this domain (exon A2 in Ye et al., 1997) . Thus exon A2 might disrupt a potential TAD or be a negative regulatory domain. The functional role of the other alternatively spliced exons identi®ed in HFH-11 and in WIN is unclear at present. The DNA binding site to which MPP2 and its homolog bind, has been de®ned by three dierent groups (Korver et al., 1997a; Ye et al., 1997; Yao et al., 1997) . We have tested these slightly dierent binding sites in a minimal tk-luciferase reporter gene construct. The HFH-11 #24 site (Ye et al., 1997) , one of the best in our experiments, was used in our study. However only weak transactivation was seen with full-length MPP2 in dierent cell lines, including RK-13 (Figures 7 ± 9) , CV-1, and NIH3T3 cells (data not shown). It is unclear why we see only weak activation in our transfection assays as compared to the robust stimulation observed by Ye et al. (1997) . One possibility is that a construct with ®ve binding sites (Ye et al., 1997) is signi®cantly better activated than one with three sites (as in our reporter). We have not addressed this possibility. It is also possible that the Caco-2 cells used by Ye et al. (1997) contain a stimulating activity that is not present in our cells or, for that matter, our cells might express an inhibitory activity which is not present in the Caco-2 cells. In this respect we note that the transactivating activity of MPP2 is substantially stimulated by cyclin/CDKs (our unpublished data). Variations in the amount of these kinase activities in cells might be responsible for the observed dierences in the transcriptional activity of MPP2 in dierent cell types. It will be important to de®ne the precise contribution of dierent cyclin/CDK complexes to the regulation of MPP2 (see below) with respect to the role of this protein in cell growth control as discussed above.
Presently little information regarding the regulation of MPP2 is available. MPP2 was originally identi®ed as a protein that is hyperphosphorylated in mitosis (Westendorf et al., 1994; Matsumoto-Taniura et al., 1996) . This ®nding provides evidence for cell cycledependent changes in MPP2 phosphorylation. Whether this phosphorylation has functional consequences is presently unclear. Several transcription factors, including Oct-1, c-Myb, and GHF-1, have been shown to be hyperphosphorylated during mitosis which correlates with inhibition of their DNA binding activity (Segil et al., 1991; LuÈ scher and Eisenmann, 1992; Caelles et al., 1995) . In addition to alterations in the chromatin structure and eects on the basal transcriptional machinery, negative regulation of transcription factors by phosphorylation might be a mechanism to reversibly inhibit gene transcription during mitosis (for review see Gottesfeld and Forbes, 1997) . Such a mechanism might also be in operation for MPP2. Interestingly MPP2 has 18 S/T-P motifs which might serve as phosphoacceptor sites for cell cycle-and/or signal-dependent phosphorylation. However none of the in vivo phosphorylation sites have been mapped so far. Thus several potential mechanisms that might regulate the phosphorylation status of MPP2 and by this its function can be envisaged and are presently under investigation.
We do not know how E7 stimulates the transcriptional activity of MPP2. One possibility is that E7 might mimick cyclin/CDK-dependent phosphorylation, in analogy to the role of E7 in aecting the function of p105RB. Our preliminary ®ndings indicate that MPP2 phosphorylation does not aect binding to E7. MPP2 phosphorylated in vitro with extracts derived from either interphase or from M phase cells was capable to bind to E7 (JM Westendorf, unpublished observation). It will now be important to determine more precisely the molecular role of E7 in activating MPP2.
In summary our study has identi®ed MPP2 as a novel interaction partner of HPV16 E7. MPP2 is a transcription factor of the fkh domain family and the available evidence suggests that this protein is involved in cell growth control. However further analyses will be required to de®ne in more detail the molecular function of MPP2 in the regulation of cellular growth. Nevertheless the combined data support a model in which E7 stimulates S phase progression and transformation by targeting MPP2 in addition to several other cellular proteins.
Materials and methods
Two-hybrid selection
DNA sequences encoding E7 and mutants thereof were cloned into p414M25LexN (based on pRS414MET25, Mumberg et al., 1994; Firzla et al., 1987 Firzla et al., , 1991 . The twohybrid selection was performed essentially as described in Hollenberg et al. (1995) with the S. cerevisiae strain L40 (MATa trp1 leu2 his3 LYS2::(lexA) 4 -HIS3 URA3::(lexA) 8 -lacZ) (Vojtek et al., 1993) . L40 cells containing the pLexA ± E7(42 ± 98) target plasmid were transformed with a cDNA library derived from 9.5 ± 10.5 days post-coitus CD1 mouse embryos fused to the activation domain of Herpes simplex viral protein 16 (Triezenberg et al., 1988; Hollenberg et al., 1995) , to give 6610 6 primary transformants. To select for strongly interacting proteins and to decrease background, 25 mM aminotriazol was included in the selective medium. From 30 colonies that tested positive for growth on medium lacking histidine and for expression of b-galactosidase, plasmids were isolated after lyticase (Sigma) treatment of the yeast cells and ampli®ed in HB101 bacteria using minimal medium lacking leucine. They were then introduced into L40 cells together with pLexA-E7(42-98) or control plasmids p414M25LexN, pLexA-myc, which contains aa 49 ± 101 of human c-Myc, pLexA-fos, which contains aa 1 ± 171 of v-fos, or pLexA-lamin, which contains aa 66 ± 230 of human lamin C (Vojtek et al., 1993) . The resulting cells were analysed for b-galactosidase expression to assess the speci®city of the interaction between the target protein and sequences encoded in the library plasmid.
Cloning and sequencing of human and mouse MPP2 cDNAs
The 5' EcoRI ± EcoNI fragment (607 bp) of the previouslydescribed partial-length MPP2 cDNA (clone 5-3) (Westendorf et al., 1994) was isolated, random-labeled with 32 P-adCTP (3000 Ci/mmol), and hybridized with replica ®lters containing DNA from 2610 6 plaques derived from 2 lZapII libraries (one a generous gift from P Chambon, the other a Uni-ZAP XR library from Stratagene) containing cDNAs reverse-transcribed from HeLa cell mRNA. In all, 12 new cDNA clones were obtained and clone 2C1, containing the largest cDNA insert (2760 bp), was sequenced. An open reading frame (ORF) of 762 codons was detected starting at position 198 preceded by STOP codons in all three reading frames. The insert of clone 1/5 from the two-hybrid selection was used to screen a cDNA library derived from total RNA of 11.5-day-old mouse embryos (Clontech). The two positive clones containing the longest inserts (clone 1a 1/5 and clone 5a 1/5) were subcloned and sequenced (S Andrecht and JM LuÈ scher -Firzla, unpublished) . Sequence analysis and database searches were performed with GCG and BLAST programs.
GST pull-down assays
Glutathione-S-transferase (GST) fusion proteins, GST-E7, GST-E7(2 ± 41), GST-MPP2(235 ± 335) were made from corresponding plasmids derived from pGEX-2T (Pharmacia). GST-MPP2(1 ± 477) and were made from pGEX-4T-1 and obtained from I Wierstra. GST-Max has been described previously (Bousset et al., 1993) .
MPP2 and E7 cloned into pBluescriptSK(7) and pcDNA3, respectively, were transcribed and translated in TNT reticulocyte lysates (Promega) in the presence of T3 RNA polymerase and 35 S-methionine/cysteine Translabel (ICN) or Promix (Amersham). In vitro translated hMPP2 or E7 was incubated with 100 ng of GST or GST fusion proteins together with glutathione agarose beads in F buer (10 mM Tris-HCl, pH 7.05, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 5 mM ZnCl 2 , 100 mM Na 3 VO 4 , 0.2% Triton X-100, 1 mM PMSF, 5 U/ml a 2 -macroglobulin, 2.5 U/ml pepstatin, 2.5 U/ml leupeptin, 0.15 mM benzamidine, 2.8 mg/ml aprotinin) (OelgeschlaÈ ger et al., 1995) overnight at 48C. The glutathione beads were then washed three times with F buer containing 400 mM NaCl and the bound proteins eluted with sodium-dodecyl-sulfate (SDS) sample buer prior to electrophoresis on SDS-polyacrylamide gels and¯uorography.
Transactivation and transformation assays
Transient transfections in RK-13 rabbit kidney or COS-7 cells were performed as described previously (Chen and Okayama, 1988; Firzla et al., 1991; OelgeschlaÈ ger et al., 1995) using the b-galactosidase expression vector pEQ176 for standardization. These transient transfection experiments were performed at least three times in duplicates or triplicates. As reporter plasmids p(Gal) 4 -tk-luc (Janknecht et al., 1993) , which contains four Gal4 binding sites, and p(MBS) 3 -mintk-luc, which contains three MPP2 binding sites (HFH-11 #24, Ye et al., 1997) were used. For expression of Gal4 fusion proteins, sequences encoding E7(2-98), E7(2-41), and E7(42-98) were cloned into the poly-linker of pGallinker-HA, a derivative of pABgal-linker HA (Schmitz and Baeuerle, 1991) . Gal4-Fos and Gal4-Myc(1-262) were obtained from T Kouzarides and C Dang, respectively (Kato et al., 1990; Bannister and Kouzarides, 1995) . For expression of unfused E7 and MPP2 proteins, the entire E7 sequence from plasmid p858 (Phelps et al., 1988) and p1657, p1658 and p1659 (Phelps et al., 1992) or the entire hMPP2 sequence from pBS2C1 was placed under control of the CMV promoter of pEQ1762P2 (Firzla et al., 1991) to give pP2E7, pP2E7D52 ± 57, pP2E7D65 ± 72, pP2E7D79 ± 86 or pP2hMPP2, respectively. Existing restriction enzyme sites in the MPP2 sequence were used to create the deletion mutants MPP2D426 ± 567 and MPP2D588 ± 743. The sequences of HPV16 and HPV6 E7 (De Villiers et al., 1981) were cloned into the pcDNA3 vector (Invitrogen) with an N-terminal Flag epitope. The hMPP2 ORF was also cloned into pSP (Kretzner et al., 1992) for expression under the control of the SV40 early promoter (pSPhMPP2). All constructs were analysed on Western blots for protein expression either with MPP2-speci®c antibodies (SantaCruz, sc502), with FLAGepitope-speci®c monoclonal antibodies (Kodak), with HPV6 E7-speci®c antisera (495A), or with HPV16 E7-speci®c antisera (2481, Firzla et al., 1987) .
Transformation activity was tested essentially as described previously (Cerni et al., 1995) . Primary rat embryo ®broblasts (REFs, obtained from C Cerni) were transfected with a plasmid encoding neomycin resistance (pRSVneo, Gorman et al., 1983) plus various combinations of plasmids containing activated Ha-Ras (pras, Cerni et al., 1989) , HPV16 E7 (pP2E7), hMPP2 (pSPhMPP2) or no insert. Two days after transfection, the cells of each dish were trypsinized and replated onto six 6 cm dishes. The cells were fed 1 day later and every 3 days thereafter with fresh medium containing 0.2 mg/ml geneticin. After 14 days, the resulting colonies were ®xed, stained with Giemsa, and counted.
In vivo binding between hMPP2 and E7
For in vivo interaction assays COS-7 cells were transfected with pP2E7 and pP2hMPP2 or control plasmids and then metabolically labeled with 35 S-methionine for 30 min. Whole cell extracts were prepared in F buer and ®rst incubated with MPP2-speci®c antibodies or irrelevant antibodies (rabbit anti-mouse IgG from Dianova) and protein A-Sepharose beads for 1 h at 48C. The resulting immunocomplexes (1st IP in Figure 4 ) were washed twice with F buer and coimmunoprecipitated proteins were eluted by incubating twice for 5 min at room temperature in antibody (AB) buer (20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM EDTA; 0.5% NP-40, 0.5% deoxycholate, 0.5% SDS, 0.5% aprotinin). The supernatants were then cleared with irrelevant antibodies plus protein A-sepharose beads (2nd IP) prior to the ®nal immunoprecipitation with E7-speci®c antiserum (3rd IP). The beads were then washed twice with RIPA buer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% NP40, 1% DOC, 0.1% SDS, 0.5% aprotinin), once with high-salt buer (10 mM Tris-HCl pH 7.4, 2 M NaCl, 1% NP40, 0.5% DOC) and once again with RIPA buer (LuÈ scher and Eisenman, 1988) . The proteins were separated by SDS ± PAGE and visualized by phosphor-imaging.
